The formulation came from a GMP-certified supplier in Uttarakhand, India, and was extracted at the All India Institute of Ayurveda in New Delhi with a 70:30 ethanol–water mixture. Investigators macerated a 25-gram sample for eight hours with stirring at 300 rpm and then for 16 additional hours without stirring. Following filtration through Whatman No. 42 paper and a 0.22-micrometer PTFE membrane, the extract was concentrated by rotary evaporation at 40 °C under reduced pressure and stored at −20 °C in amber vials. For chemical analysis, the extract was separated on a C18 UHPLC column during a 30-minute gradient run at 0.3 milliliters per minute. High-resolution mass spectra were acquired in positive and negative electrospray ionization modes, with data-dependent top-five MS2 fragmentation. Peak detection, centroiding and chromatogram alignment were followed by mass-error screening at no more than 5 ppm, retention-time alignment within 0.2–0.3 minutes and quality-control checks. The analysis tentatively identified 109 compounds in negative mode and 259 in positive mode. Some assignments met Level 2 MSI criteria, based on spectral and retention-time matches, while confirmation with reference standards enabled Level 1 identification.

The detected compounds entered an in silico screening pipeline intended to prioritize constituents that might plausibly reach the brain. SwissADME and Molsoft were used to examine absorption, distribution, metabolism, excretion, toxicity, Lipinski’s Rule of Five and blood–brain barrier status. Canonical chemical structures obtained from PubChem were submitted to SwissTargetPrediction, with predicted targets retained when their probability was at least 0.10. Separately, the team collected mild-cognitive-impairment genes from NCBI Gene and GeneCards, applying a relevance threshold of at least 10 to GeneCards entries. After duplicate entries were removed, the analysis contained 1,204 predicted compound targets and 16,035 disease-associated genes. Their intersection produced 942 shared genes, which were carried into protein-interaction and functional analyses. These filters and intersections were computational prioritization steps, not measurements of blood concentrations, brain exposure or target modulation.

Cytoscape, STRING and CytoHubba analyses ranked AKT1, TP53, TNF, SRC, IL6, EGFR, CTNNB1, STAT3, ESR1, HSP90AA1, CASP3, JUN, BCL2, HIF1A and PPARG among the leading network genes. Gene Ontology enrichment linked the network with protein and enzyme binding, transcriptional regulation, apoptosis, inflammatory responses, oxidative-stress signaling and synaptic transmission. KEGG results included Alzheimer’s disease, PI3K–AKT, MAPK, TNF, apoptosis, HIF-1, estrogen and Wnt/β-catenin signaling, along with IL-17, NOD-like receptor and C-type lectin receptor signaling. The network consequently associated the formulation with several mechanisms relevant to MCI, including inflammation, cell survival, metabolism and programmed cell death. It also showed overlap with pathways marked in the paper for Alzheimer’s, Huntington’s and amyotrophic lateral sclerosis, but the analysis does not demonstrate that any of these genes changes in an individual with MCI.

Molecular docking prioritized AKT1 with isoferulic acid, PPARG with arctigenin and TNF with 3,6,2′-trimethoxyflavone. Their respective predicted scores were −8.010, −7.647 and −7.891 kilocalories per mole. Hydrogen bonds, hydrophobic contacts and π–π interactions supported the selected poses. Isoferulic acid was predicted to interact with AKT1 residues including GLN61, TYR151, TYR59, TYR119, SER60 and LEU57. Arctigenin formed hydrogen bonds with HIE449, TYR473 and SER289 in PPARG, while the TNF–trimethoxyflavone model showed polar and hydrophobic contacts involving residues such as GLN61, TYR151 and TYR59. Donepezil and lecanemab were docked under the same reported conditions, receiving scores of −5.635 and −6.121 kilocalories per mole, respectively. The numerical comparison favored the three selected plant compounds, but the authors cautioned that docking scores alone do not predict biological efficacy or clinical performance. Exact receptor-grid coordinates and dimensions were not retained in the available records, and no retrospective redocking or ligand-pose RMSD validation was performed.

Density functional theory calculations examined the electronic properties of isoferulic acid, arctigenin and 3,6,2′-trimethoxyflavone using Gaussian 16. Their structures were optimized with the B3LYP hybrid functional and 6-31G(d,p) basis set, with solvent effects treated using the IEFPCM model; frequency analyses indicated that the optimized structures had no imaginary frequencies. Isoferulic acid had an ionization potential of 5.68 electron volts, an energy gap of 4.13 electron volts and an electrophilicity index of 3.16 electron volts. The trimethoxyflavone had a similar 4.27-electron-volt gap and the highest reported electrophilicity value, 3.27 electron volts. Arctigenin differed sharply, with an 8.45-electron-volt ionization potential, a 12.01-electron-volt gap and an electrophilicity index of 0.50 electron volts. These calculations characterize predicted electronic reactivity and chemical stability; they do not measure binding, metabolism or biological activity in cells or animals. The documented protocol did not specify a nondefault self-consistent-field setting or apply a separate empirical dispersion correction.

Each selected complex was then examined in one 500-nanosecond molecular dynamics trajectory in Schrödinger Maestro. The systems were solvated with TIP3P water, surrounded by a 10-ångström buffer and neutralized with sodium ions; the simulations used a constant-particle-number, constant-pressure and constant-temperature ensemble at 300 K. No independent replicate simulations were performed. The TNF complex showed backbone root-mean-square deviations of approximately 1.2 to 3.2 ångströms, while PPARG remained between about 1.0 and 3.0 ångströms. AKT1 was more flexible, reaching approximately 4.0 ångströms, which the authors interpreted as conformational variation rather than outright destabilization. Ligand motions followed the corresponding protein motions in all three systems, supporting continued retention near the predicted binding regions. Residues associated with the predicted binding interfaces showed lower fluctuations than peripheral loops and terminal regions. Hydrogen bonds, hydrophobic contacts and water bridges persisted over substantial portions of the trajectories, while radius of gyration and solvent-accessible surface area remained comparatively stable.

Post-simulation analysis used backbone alignment, principal component analysis and molecular mechanics with generalized Born surface area calculations. The AKT1 and PPARG systems formed relatively compact principal-component trajectories, while TNF showed a more elongated distribution that nevertheless retained endpoint clustering. Free-energy landscapes differed among the complexes: PPARG had the widest and deepest reported low-energy basin, whereas AKT1 and TNF explored more elevated conformations. MM-GBSA estimated mean binding free energies of −74.87 ± 4.94 kilocalories per mole for AKT1 with isoferulic acid, −74.81 ± 5.24 for PPARG with arctigenin and −74.87 ± 5.01 for TNF with trimethoxyflavone. The van der Waals and lipophilic terms contributed strongly to these modeled values, while hydrogen-bond terms were comparatively small. Because the study used a single trajectory per complex without independent replicates, these results are computational estimates under the specified conditions rather than experimentally observed binding energies or measurements of biological activity.

The study’s central result is a prioritization result: three phytochemicals from Guduchyadi Yoga formed computationally persistent complexes with proteins embedded in pathways associated with mild cognitive impairment and broader neurodegeneration. The work combines chemical profiling with network pharmacology, electronic-structure calculations, docking and long-duration molecular dynamics, creating mechanistic hypotheses for further testing. Important gaps remain. The researchers did not perform retrospective redocking or ligand-pose RMSD validation, and the exact receptor-grid settings could not be verified from the available records. The formulation was not tested in people with MCI, and the study did not show changes in symptoms, cognition or disease progression, nor did it demonstrate that any compound modulated its proposed target in a biological system. The findings therefore identify compounds and protein interactions for biochemical, animal and appropriately designed clinical evaluation, rather than establish a treatment effect or support clinical recommendations.

Subject of Research: Computational profiling of Guduchyadi Yoga phytochemicals and their modeled interactions with MCI-related proteins

Article Title: Chemical characterization and computational validation of Guduchyadi Yoga in mild cognitive impairment: UHPLC-HRMS, network pharmacology, docking, DFT, dynamics, and post dynamics analysis.

Article References: Yadav, P., Badal, R., Jayaraman, A., Venkatachalapathy, R., Ghildiyal, S., Rai, S., Kumar, R. C. S., Bhide, B., Sherkhane, R., & Nesari, T. (2026). Chemical characterization and computational validation of Guduchyadi Yoga in mild cognitive impairment: UHPLC-HRMS, network pharmacology, docking, DFT, dynamics, and post dynamics analysis.. Results in Chemistry, 31, Article 103983. https://doi.org/10.1016/j.rechem.2026.103983

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103983

Keywords: Guduchyadi Yoga, mild cognitive impairment, UHPLC-HRMS, network pharmacology, molecular docking, molecular dynamics, AKT1, PPARG, TNF, Ayurvedic formulation, Chemical, characterization

The research team, led by Tamiris Invencioni Moraes Stefani, Thiago Dominguez Crespo Hirata and Alvaro Cerda, set out to test whether variants in ten candidate genes—FTO, LEP, LEPR, ADRB3, ADIPOQ, TCF7L2, ENPP1, APOA5, PPARG and CYP11B2—were associated with metabolic syndrome and obesity-related traits. These genes were chosen because genome-wide association studies and candidate gene analyses had previously implicated them in obesity, diabetes, dyslipidemia and blood pressure regulation. The participants, aged 18 to 83, were randomly selected from a Brazilian observational cohort, with 179 diagnosed with metabolic syndrome under International Diabetes Federation criteria and 241 serving as controls. Individuals with kidney, liver, thyroid or adrenal disease, gonadal dysfunction, secondary obesity or pregnancy were excluded.

The methodological rigor of the study deserves attention. Each participant underwent a detailed clinical and anthropometric evaluation, including body mass index, waist circumference, waist-to-hip ratio, body fat percentage and basal metabolic rate. Fasting blood samples yielded an extensive laboratory panel: glucose, glycated hemoglobin, insulin, a full lipid profile, apolipoproteins, adipokines such as leptin and adiponectin, and a battery of inflammatory markers including high-sensitivity C-reactive protein, interleukin-6, interleukin-1 beta, tumor necrosis factor alpha and plasminogen activator inhibitor 1. Insulin resistance was quantified both by the HOMA-IR index and by the triglyceride-glucose index. Genomic DNA was extracted from leukocytes and variants were genotyped using TaqMan assays, with control samples in every run and twenty percent of samples re-analyzed with complete concordance.

When the researchers applied multivariate logistic regression—adjusting for age, ethnicity, sex, alcohol consumption, tobacco smoking, physical activity and family history of cardiovascular disease—two variants stood out as independent predictors of metabolic syndrome. The G allele of ADRB3 rs4994, a missense change known as Trp64Arg, more than tripled the odds of the syndrome, with an odds ratio of 3.71. The G allele of LEPR rs1137100, the Lys109Arg variant in the leptin receptor, nearly doubled the risk, with an odds ratio of 2.52. Both variants were also associated with hypertension, and the ADRB3 risk allele additionally predicted dyslipidemia, insulin resistance and obesity.

The biological logic behind these associations is compelling. The ADRB3 gene encodes the beta-3 adrenergic receptor, which sits on the surface of adipose tissue cells and drives lipolysis, thermogenesis and energy expenditure. The Trp64Arg substitution lies in the intracellular tail of the receptor and is thought to impair its signaling, effectively dampening the body’s ability to burn fat. Carriers of the risk allele in this study showed higher body mass index, larger waist circumference in women, greater body fat, elevated glucose, insulin, triglycerides and HOMA-IR, and a strikingly pro-inflammatory profile, with increased leptin, PAI-1, hsCRP, IL-1 beta, IL-6 and TNF-alpha. The leptin receptor variant, meanwhile, alters the stability of the receptor’s ligand-binding domain, potentially weakening the leptin-melanocortin pathway that governs satiety and body weight.

Beyond the two strongest hits, variants in FTO and PPARG shaped the anthropometric, metabolic and inflammatory landscape of the cohort. The FTO rs17817449-G allele predicted higher waist-to-hip ratio in women along with lower apolipoprotein AI and resistin concentrations, echoing earlier findings in Chinese adults and in Brazilians with severe obesity. FTO is an intronic risk locus whose variants are believed to disrupt regulatory interactions that control energy homeostasis. The PPARG rs1801282 variant, Pro12Ala in the nuclear receptor that orchestrates adipogenesis and insulin sensitivity, predicted higher body fat in women and higher leptin in men—a gender-dependent effect that underscores how genetic risk can be expressed differently across sexes.

The study’s most forward-looking contribution is its polygenic risk score. Rather than treating each variant in isolation, the team built a weighted score in which each individual’s risk alleles were summed using adjusted odds ratios derived from their own regression models. Because genotyping success varied across participants, the researchers also computed a normalized score, dividing each person’s total by the number of successfully genotyped variants. Both versions of the score told the same story: values were significantly higher in people with metabolic syndrome, and they climbed steadily as the number of metabolic syndrome components increased from zero to five. Quartile analysis revealed a dose-response relationship, with syndrome prevalence rising progressively from the lowest to the highest genetic burden category.

The discriminatory power of the score, however, was modest. Receiver operating characteristic analysis yielded an area under the curve of 0.598 for the raw score and 0.616 for the normalized version—statistically significant but far from a stand-alone diagnostic test. The authors are candid about why: the score was built from a restricted set of candidate genes rather than genome-wide data, and the cohort, while carefully phenotyped, was relatively small and cross-sectional. Large genome-wide polygenic models, such as a recent multivariate analysis of nearly five million people of European and East Asian ancestry, achieve better discrimination by leveraging hundreds of loci. Yet those models transfer poorly to admixed populations like Brazil’s, which is precisely where a biologically informed candidate gene approach offers complementary value.

The limitations of the study are acknowledged with unusual transparency. The cross-sectional design precludes causal inference. Multiple comparisons were corrected using the Benjamini-Hochberg method at a ten percent false discovery rate, but some associations may still be influenced by the sheer number of tests. Deviations from Hardy-Weinberg equilibrium were observed for several polymorphisms, notably in the two variants most strongly associated with the syndrome, where deviations appeared only in the control group—a pattern the authors interpret as consistent with differential selective pressure rather than genotyping error. Many participants, particularly those with metabolic syndrome, were taking antidiabetic, antihypertensive or lipid-lowering medications, which may have blunted some genotype-phenotype associations. Self-reported ethnicity, without ancestry-informative markers, limits full control of population stratification in this admixed cohort.

Even with these caveats, the findings carry real weight for precision medicine in underrepresented populations. They confirm that variants governing energy homeostasis—ADRB3, LEPR and FTO—and lipid metabolism through PPARG are not merely statistical signals but are reflected in measurable differences in body composition, insulin resistance, lipid transport and systemic inflammation. The clear gradient of polygenic risk across the number of metabolic syndrome components supports the idea that common variants with individually modest effects accumulate into meaningful susceptibility. As the authors conclude, further studies in diverse populations will be essential before such scores can enter clinical practice, but this work marks an important step toward genetically informed assessment of metabolic and cardiovascular risk in a population that genome-wide resources have long overlooked.

Subject of Research: Genetic variants and polygenic risk scores associated with obesity-related metabolic syndrome in Brazilian adults

Article Title: ADRB3, LEPR, FTO and PPARG variants contribute to obesity-related metabolic syndrome in Brazilian adults: a polygenic risk score approach

Article References: Stefani, T. I. M., Hirata, T. D. C., Cerda, A., de Oliveira, R., dos Santos, M. A., Fajardo, C. M., Dorea, E. L., Bernik, M. M. S., Hirata, M. H., & Hirata, R. D. C. (2026). ADRB3, LEPR, FTO and PPARG variants contribute to obesity-related metabolic syndrome in Brazilian adults: a polygenic risk score approach. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02218-9

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02218-9

Keywords: metabolic syndrome, obesity, polygenic risk score, ADRB3, LEPR, FTO, PPARG, genetic variants, insulin resistance, inflammation, Brazilian cohort, cardiovascular risk

The research team, led by investigators including Xin Gao and Deqing Hu of Tianjin Medical University, assembled an enormous chromatin accessibility dataset drawn from 208 single-cell ATAC sequencing samples. These samples spanned healthy adult and fetal tissues, peripheral blood from healthy donors and patients with systemic lupus erythematosus, precancerous familial adenomatous polyposis lesions, and tumors from colorectal, clear cell renal cell, ovarian, and endometrial cancers. After computational integration and batch correction using the ArchR framework, the myeloid compartment resolved into fourteen clusters, five of which were macrophage populations with strikingly distinct tissue distributions and functional signatures.

Two of those populations stood out. Macro-SPP1 cells, defined by expression of the secreted phosphoprotein SPP1, were concentrated in cancerous tissues and showed elevated activity of genes such as IL10, PPARG, INHBA, and IL4I1, along with strong wound healing, hypoxia, and angiogenesis signatures. Macro-C1QC cells, enriched in precancerous polyp tissue, carried markers of tissue-resident macrophages such as FOLR2 and MRC1 alongside anti-inflammatory programs. Motif analysis of their open chromatin revealed candidate regulators: NF-κB-related and bZIP factors dominated the accessible regulatory regions of Macro-SPP1, whereas bHLH and C2H2 zinc finger factors marked Macro-C1QC.

To connect these accessibility patterns to gene output, the researchers integrated the chromatin data with a published pan-cancer single-cell transcriptome of myeloid cells and computed peak-to-gene links, correlations between the accessibility of regulatory elements and the expression of their target genes. Super-enhancer analysis then identified the most densely wired regulatory hubs in each population. In Macro-SPP1, the top super-enhancer-linked genes included chemokines and SOD2, and the full set of 162 high-confidence super-enhancer-regulated genes was enriched for inflammatory response, IL-10 signaling, angiogenesis, wound healing, and HIF-1 signaling. When the team scored these genes in bulk tumor data from The Cancer Genome Atlas, high signature scores predicted poor overall survival in 18 of 29 cancer types. Notably, the predicted fraction of M2-like macrophage infiltration did not track with prognosis, suggesting that the specific enhancer-driven transcriptional program, rather than the sheer number of suppressive macrophages, is what matters for patient outcomes.

Pseudotime trajectory analysis then addressed the question of where these cells come from. The results supported two divergent routes to a pro-tumorigenic identity. Macro-SPP1 cells appeared to descend from peripheral monocytes through an intermediate Mono-NLRP3 stage, while Macro-C1QC cells seemed to arise from resident Macro-LYVE1 macrophages already embedded in tissue. Along the monocyte route, early activation of inflammatory chemokines, IL1B, and THBS1 was followed later by IL10, with NF-κB and AP-1 family factors initiating the process and PPARG and NFAT5 driving the terminal state. The tissue-resident route instead involved CCL3 and CCL4 chemokines and factors such as PRDM1, HES1, ETV5, and MAF. The identification of NFAT5, a transcription factor best known for mediating adaptation to hyperosmotic stress, as a key regulator alongside PPARG and the chromatin-binding protein MECP2 was particularly intriguing, hinting that TAMs activate a broad stress-adaptation program to survive the metabolically hostile tumor microenvironment.

To test these candidates experimentally, the team used the standard THP-1 monocyte model, differentiating cells into macrophages and polarizing them toward inflammatory M1 states with interferon-gamma and lipopolysaccharide, or suppressive M2 states with interleukin-4. NFAT5, PPARG, and MECP2 were all upregulated during M2 polarization, and CRISPR-Cas9 knockdown of any of the three significantly reduced the M2 population, as measured by diminished expression of markers such as CD206 and CD163, while leaving M1 differentiation largely intact. The same results held when macrophages were exposed to conditioned medium from colorectal cancer cells, a more tumor-like stimulus, reinforcing the link between these factors and pro-tumorigenic polarization.

The most conceptually significant part of the study concerned how the relevant enhancers actually work. Enhancers can activate genes in two ways: by opening promoter chromatin so that the transcription preinitiation complex can assemble, or by releasing RNA polymerase II that has initiated transcription but stalled just downstream of the transcription start site. Classifying TAM-associated genes by whether their expression tracked promoter or enhancer accessibility, the researchers found that 71.2 percent of genes linked to Macro-SPP1 regulatory elements were so-called type E genes, whose promoters remained constitutively accessible across all cell states while only their enhancers changed. These type E genes, which included CCL2, HIF1A, CD274, and NFAT5, were also significantly enriched for fine-mapped cancer-risk variants from genome-wide association studies, unlike regulatory elements linked to other macrophage populations.

Constitutively open promoters with dynamically regulated enhancers are precisely the configuration in which pause-release operates, a paradigm well established in embryonic development. Re-analysis of RNA polymerase II ChIP-seq data from mouse macrophages confirmed the prediction: type E genes showed pronounced polymerase pausing in resting macrophages, and that pausing dropped sharply upon interleukin-4 stimulation, the signal that drives alternative, tumor-supportive polarization. The team then dissected the gene HIPK2, a type E gene whose product dampens NF-κB signaling. Disrupting individual HIPK2 enhancers with CRISPR-Cas9 reduced HIPK2 expression, lowered M2 marker expression at both RNA and protein levels, and, critically, increased polymerase occupancy at the transcription start site while depleting it from the gene body, the molecular fingerprint of enhanced pausing. Disrupting an upstream enhancer of NFAT5 produced a parallel loss of M2 polarization.

Taken together, the study sketches a sequential regulatory cascade for the monocyte-derived TAM route: AP-1 factors respond first to tumor infiltration, NF-κB drives an inflammatory phase, and that inflammation is then resolved into a pro-repair, immunosuppressive phenotype through PPARG and NFAT5 acting at super-enhancers that liberate paused polymerase at genes governing wound healing, angiogenesis, and immune suppression. The authors propose that blocking this pause-release mechanism with epigenetic or transcriptional inhibitors could strip tumors of their macrophage allies and potentially overcome resistance to checkpoint immunotherapy, a strategy conceptually distinct from simply depleting macrophages or blocking their recruitment.

The work carries caveats that the authors themselves acknowledge. The polymerase pausing data derive from mouse macrophages rather than human TAMs, so direct ChIP-seq in patient samples will be needed for definitive validation, and the survival analysis relies on bulk tumor data that cannot unambiguously assign gene expression to specific cell types. The in vitro polarization systems, while informative, are simplified stand-ins for the complex tumor microenvironment. Even so, by unifying single-cell chromatin maps across cancers, trajectory modeling, GWAS variant enrichment, and mechanistic perturbation experiments, the study delivers one of the most complete pictures to date of how human tumors reprogram macrophages at the level of cis-regulatory DNA, and it nominates a concrete set of enhancers, transcription factors, and polymerase dynamics as targets for the next generation of macrophage-directed cancer therapies.

Subject of Research: Epigenetic regulation of tumor-associated macrophage differentiation via enhancer-controlled RNA polymerase II pausing

Article Title: Pan-cancer epigenetic landscape of human tumor-associated macrophages reveals crucial enhancers governing their heterogenous formation by Pol II pausing modulation

Article References: Xiong, C., Ning, H., Wang, X., Xie, Y., Liu, Z., Hu, D., & Gao, X. (2026). Pan-cancer epigenetic landscape of human tumor-associated macrophages reveals crucial enhancers governing their heterogenous formation by Pol II pausing modulation. Journal of Advanced Research, 88, 929-945. https://doi.org/10.1016/j.jare.2026.01.048

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.048

Keywords: tumor-associated macrophages, enhancers, RNA polymerase II pausing, single-cell ATAC-seq, super-enhancers, NFAT5, PPARG, tumor microenvironment, macrophage polarization, cancer immunotherapy, epigenetics, pan-cancer analysis

The research, conducted by Rachel Giles, Chrisna Durandt, Melvin A. Ambele and Michael S. Pepper at the University of Pretoria, tackles a bottleneck that has long constrained obesity research. Most laboratory models of adipogenesis—the process by which undifferentiated cells mature into lipid-filled fat cells—rely on murine cell lines such as the immortalized 3T3-L1 preadipocyte line derived from mouse embryos. Although these models are well established, human cells offer greater physiological compatibility and relevance to human disease. The South African team therefore turned to adipose-derived stromal/stem cells, or ASCs, which are isolated from adipose tissue and possess a strong natural capacity to differentiate into adipocytes. Because these cells are of human origin, findings obtained with them are more likely to translate reliably into the clinical setting, making them an excellent platform for studying human fat cell formation in a dish.

Adipogenesis itself is a tightly choreographed biological program. Multipotent mesenchymal stromal/stem cells first commit to the preadipocyte lineage and then accumulate intracellular lipid droplets as they mature into adipocytes. Researchers typically quantify this process in two complementary ways: by measuring the accumulation of lipid droplets inside the cells, a morphological hallmark of differentiation, or by tracking the expression of genes associated with adipogenesis. Both approaches have historically been performed in large 6-well or 12-well culture plates, formats that consume substantial quantities of cells, reagents and time. Screening a library of 100 potential anti-obesity compounds in triplicate under such conditions quickly becomes prohibitively expensive, which is precisely the problem the Pretoria group set out to solve by asking whether adipogenic differentiation could be reliably monitored in much smaller wells.

To answer that question, the team isolated ASCs from adipose tissue donated by patients undergoing liposuction, with informed consent and approval from the university’s Research Ethics Committee. The cells were expanded in complete growth medium and characterized by flow cytometry, showing the expected surface marker profile: positive for CD44, CD73 and CD90, and negative for CD34, CD45 and CD105. The absence of CD105 deviates slightly from the minimal criteria recommended by the International Society for Cell and Gene Therapy and the International Federation for Adipose Therapeutics and Science, but the researchers note that CD105 expression is known to vary with culture conditions, and previous work has shown that CD105-negative mesenchymal stromal cells retain full differentiation potential across all three mesodermal lineages. Consistent with that literature, the cells in this study differentiated robustly into adipocytes when induced.

The experimental design was elegantly systematic. ASCs were seeded into 6-, 12-, 24-, 48- and 96-well plates, with plating densities adjusted to each well size, and driven to differentiate over 21 days using a cocktail of adipogenic inducers: the phosphodiesterase inhibitor IBMX, insulin, the cyclooxygenase inhibitor indomethacin and the glucocorticoid dexamethasone. Non-induced cultures served as undifferentiated controls. Lipid accumulation was then assessed on days 0, 14 and 21 using four independent readouts: fluorescence microscopy, flow cytometry, reverse transcription quantitative polymerase chain reaction (RT-qPCR) and spectrophotometry. Under the microscope, induced cultures in every well size displayed cells studded with multiple intracellular lipid droplets stained by the fluorescent dye Nile Red, while non-induced controls showed only low-level background fluorescence attributable to endogenous cellular fluorophores such as flavins and flavoproteins. By day 21, some cells harbored enlarged droplets, hinting at the droplet merging that characterizes fully mature adipocytes in living tissue.

Flow cytometry provided quantitative confirmation. The proportion of Nile Red-positive cells was highest in the standard 6-well format, reaching 41.85 percent on day 14 and 38.38 percent on day 21, but substantial differentiation was also detected in every smaller format, including roughly 30 percent of cells in the 96-well plates. Differences between days 14 and 21 were not statistically significant, and the only significant differences among plate sizes on day 14 were between the 6-well plate and the 24- and 48-well plates. Spectrophotometry, which measures the optical density of the lipid dye Oil Red O extracted from stained cells and normalized to cell count, likewise showed elevated lipid content in induced cultures across all well sizes, with no significant differences between formats on either measurement day. One technical wrinkle emerged: unbound Oil Red O tended to stick to the plastic of smaller wells, inflating optical density readings in non-induced controls as well size decreased.

The gene expression data told a similar story, with an important caveat. Induced cultures upregulated the key adipogenic transcription factors PPARG and CEBPA—PPARγ being the master regulator of fat cell formation—together with the PPARγ-responsive genes CD36 and FABP4, which mark terminally differentiated adipocytes. Expression levels were statistically indistinguishable across the 6-, 12- and 24-well formats. However, the smaller wells yielded too few cells to extract sufficient RNA consistently, forcing the researchers to pool wells for RT-qPCR and leaving the 48- and 96-well gene expression data incomplete. Low RNA yield from the smallest formats thus stands as the principal limitation for transcript-based readouts, and the authors suggest that the RT-qPCR protocol will need optimization for low cell numbers before gene expression can serve as a truly high-throughput endpoint.

To compare the different plate sizes and methods rigorously, the team employed Bland-Altman multiple comparison plots, a statistical technique that assesses agreement between measurement approaches by examining bias and the limits of agreement. Using the 6-well plate as the reference standard, the 24-well format showed the least variability for flow cytometry and for both PPARG and FABP4 gene expression, while the 96-well plate consistently showed the highest variability. When methods were compared against each other with flow cytometry as the reference, spectrophotometry produced the tightest agreement across all well sizes on both days 14 and 21. The overall conclusion was encouraging: all well sizes were broadly comparable, meaning the choice of assay can be guided by reliability and cost rather than by fundamental incompatibility between formats.

Cost analysis drove the practical payoff home. Assuming a standard 21-day induction and including positive, negative and non-induced controls in triplicate, screening 100 compounds by spectrophotometry in 48-well plates would cost approximately R30,998, or about $1,658, making it the cheapest option by a clear margin. Flow cytometry in the same format would cost roughly $2,099, while RT-qPCR in 12-well plates—the smallest format that reliably yielded sufficient mRNA—would run to about $5,223. The researchers conclude that adipogenic differentiation of human ASCs can be quantified with confidence in 24- and 48-well plates, offering a higher-throughput, more time-efficient and more affordable approach than the traditional 6-well standard. Spectrophotometry emerges as an ideal first-pass screen for anti-adipogenic activity, with flow cytometry providing rich single-cell quantification and RT-qPCR illuminating gene-level effects at later stages of a screening pipeline. The critical next step will be validating the platform with established anti-adipogenic compounds such as PPARγ antagonists, a demonstration that would cement the assay’s utility in the hunt for the next generation of obesity therapies.

Subject of Research: Development of a high-throughput in vitro assay for monitoring adipogenesis of human adipose-derived stromal/stem cells for anti-obesity drug screening

Article Title: Development of a high-throughput assay for monitoring adipogenesis in vitro

Article References: Giles, R., Durandt, C., Ambele, M. A., & Pepper, M. S. (2026). Development of a high-throughput assay for monitoring adipogenesis in vitro. Current Research in Biotechnology, Article 100419. https://doi.org/10.1016/j.crbiot.2026.100419

Image Credits: AI Generated

DOI: 10.1016/j.crbiot.2026.100419

Keywords: adipogenesis, obesity, adipose-derived stromal/stem cells, high-throughput screening, flow cytometry, spectrophotometry, RT-qPCR, Nile Red, Oil Red O, PPARG, drug discovery, cell culture

The scale of the problem they targeted is enormous. More than nine million osteoporotic fractures occur worldwide each year, and people living with diabetes mellitus face a 20 to 50 percent higher risk of fragility fractures than the general population. Diabetic osteoporosis is increasingly described as a dual pandemic, driven by mechanisms that differ fundamentally from ordinary age-related bone loss. Advanced glycation end products, insulin resistance, oxidative stress, and elevated inflammatory cytokines all conspire to disrupt bone metabolism, lowering osteoprotegerin while raising RANKL, a signal that fuels osteoclast-driven bone resorption. At the same time, chronic inflammation and hyperglycemia push bone-forming osteoblasts toward apoptosis and steer mesenchymal stem cells away from bone formation and toward fat production, a molecular switch governed by activated PPAR-gamma and suppressed Runx-2 expression.

Because existing antidiabetic drugs manage blood glucose imperfectly and carry side effects without curing the underlying disease, the research team turned to bioinformatics to hunt for multi-target natural molecules. Their strategy began with predicting genistein’s pharmacokinetic profile using the SwissADME web tool and its oral toxicity using ProTox-II and ProTox-3.0, which returned encouraging drug-likeness scores and low predicted toxicity. They then mined the GeneCards and Comparative Toxicogenomic databases for disease targets, retrieving a staggering 32,133 genes associated with diabetes mellitus and osteoporosis, and used Swiss Target Prediction to identify 105 human protein targets for genistein itself.

Overlaying the two gene sets produced a protein-protein interaction network of 104 nodes and 606 edges, visualized in Cytoscape and analyzed through topological parameters including degree, betweenness centrality, and closeness centrality. Five hub genes rose decisively above the rest: EGFR, the epidermal growth factor receptor; ESR1, the estrogen receptor alpha; MMP9, matrix metalloproteinase-9; PTGS2, the inflammatory cyclooxygenase-2 enzyme; and PPARG, the nuclear receptor governing fat and glucose metabolism. Gene ontology and KEGG pathway enrichment analyses revealed that these targets converge on the PPAR signaling pathway and EGFR tyrosine kinase inhibitor resistance pathways, alongside biological processes spanning apoptosis regulation, stress response, growth factor signaling, and catecholamine metabolism.

The computational deep-dive then moved to the atomic scale. Molecular docking using Schrödinger’s Glide module showed genistein binding strongly to all four top targets, with the strongest standard-precision score of minus 10.752 kcal/mol against ESR1, followed by minus 8.381 against EGFR, minus 7.096 against MMP9, and minus 6.495 against PPARG. Each complex was anchored by specific hydrogen bonds and hydrophobic contacts within the binding pockets, indicating that the soy isoflavone nestles into the same active regions as purpose-built synthetic drugs.

Docking, however, captures only a frozen snapshot. To test whether these interactions survive the thermal chaos of a living cell, the team ran 100-nanosecond molecular dynamics simulations in triplicate for each protein-ligand complex using the Desmond engine at 300 Kelvin under constant pressure and temperature. All four systems equilibrated within 20 nanoseconds and remained stable throughout. Backbone root-mean-square deviations stayed between 1.8 and 2.5 angstroms, ligand RMSD values remained below 2 angstroms, and active-site residues fluctuated less than 1.5 angstroms. The ESR1 and PPARG complexes proved especially robust, maintaining three to four hydrogen bonds for roughly 80 to 88 percent of the trajectory and retaining high alpha-helical content of about 55 to 57 percent, signatures of thermodynamically stable, persistent binding.

MM/GBSA free energy calculations sealed the computational case. The ESR1 complex posted the most favorable binding free energy at minus 51.86 kcal/mol, followed by EGFR at minus 49.23 and PPARG at minus 42.82, with van der Waals, electrostatic, and nonpolar solvation terms driving the favorable energetics. These numbers confirmed that genistein’s grip on its targets is not an artifact of rigid-receptor scoring but a genuinely stable molecular partnership sustained by the same forces that govern real drug binding.

Crucially, the researchers did not stop at the computer. In a dexamethasone-induced insulin resistance rat model, a well-established experimental mimic of type 2 diabetes metabolic dysfunction, genistein was formulated as a solid dispersion with PVP-K30 to improve solubility and administered orally at 1, 2, and 4 mg/kg daily for 25 days. Post-treatment, genistein-treated rats showed statistically significant reductions in fasting blood glucose and serum insulin compared with untreated positive controls, with the highest dose performing best, indicating restored insulin sensitivity.

The skeletal results were equally compelling. Scanning electron microscopy of rat femurs revealed that diabetic control animals had porous, microcracked, eroded trabecular surfaces and visible resorption pits, while genistein-treated bones appeared dense, compact, and structurally organized. Nanoindentation showed that treated animals maintained tissue-level hardness and reduced modulus close to normal values, and three-point bending tests demonstrated dramatic mechanical recovery: maximum load capacity in the highest-dose group reached 67.4 newtons, exceeding even the normal control value of 60.81 newtons, while the untreated diabetic group collapsed to just 10.33 newtons. Ultimate stress, stiffness, and toughness all followed the same restorative pattern.

Mechanistically, the findings weave a coherent story. EGFR dysregulation impairs the PI3K/AKT insulin signaling axis and undermines osteoblast survival, while genistein’s selective affinity for estrogen receptor beta and modulation of NF-kB and MAPK pathways counteracts inflammation-driven bone resorption. MMP9, overexpressed under hyperglycemic oxidative stress, chews through bone matrix and is partially responsible for skeletal degradation in diabetic animals, and PPAR-gamma overactivation diverts bone marrow stem cells into fat rather than bone. By binding all of these targets simultaneously, genistein appears to act as a dual-action agent, lowering blood glucose while defending bone microarchitecture and mechanical strength. The authors caution that further clinical and translational work is needed, but their integrated evidence positions this inexpensive soy-derived phytoestrogen as a promising template for evidence-based functional foods and tailored therapeutics against a complication that diabetes medicine has long undermanaged.

Subject of Research: Genistein as a multi-target phytoestrogen therapy for diabetic osteoporosis, investigated through network pharmacology, molecular docking, molecular dynamics simulation, and rat model experiments

Article Title: Genistein potential and mechanisms against diabetes osteoporosis: An integrated study of network pharmacology, molecular docking, and molecular dynamics simulation

Article References: Sharma, S., Chaudhary, R., Hooda, T., Sharma, C., Dabral, S., Kumar, A., Bansal, S., & Gupta, S. (2026). Genistein potential and mechanisms against diabetes osteoporosis: An integrated study of network pharmacology, molecular docking, and molecular dynamics simulation. Results in Chemistry, 30, Article 103833. https://doi.org/10.1016/j.rechem.2026.103833

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103833

Keywords: genistein, diabetic osteoporosis, network pharmacology, molecular docking, molecular dynamics simulation, MM/GBSA, EGFR, ESR1, MMP9, PPARG, insulin resistance, bone metabolism